PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
26845171-0	2016	TGF-beta Type I Receptor Kinase Inhibitor EW-7197 Suppresses Cholestatic Liver Fibrosis by Inhibiting HIF1alpha-Induced Epithelial Mesenchymal Transition.	vactosertib	42-49	hypoxia inducible factor 1 subunit alpha	Homo sapiens	102-111
28732811-10	2017	EW7197, an inhibitor for activin receptor-like kinase 5/TGF-beta receptor I (TGFbetaR1) suppressed KA-mediated phosphorylation of Smad2.	vactosertib	0-6	SMAD family member 2	Mus musculus	130-135
27974707-7	2017	Treatment with EW-7197, a novel inhibitor of TGF-beta signaling, diminished CUG2-mediated EMT and inhibition of Akt, ERK, JNK, and p38 MAPK, non-canonical TGF-beta signaling molecules, also decreased expression of Smad2/3, Snail and Twist, leading to inhibition of EMT.	vactosertib	15-22	transforming growth factor beta 1	Homo sapiens	45-53
27974707-7	2017	Treatment with EW-7197, a novel inhibitor of TGF-beta signaling, diminished CUG2-mediated EMT and inhibition of Akt, ERK, JNK, and p38 MAPK, non-canonical TGF-beta signaling molecules, also decreased expression of Smad2/3, Snail and Twist, leading to inhibition of EMT.	vactosertib	15-22	centromere protein W	Homo sapiens	76-80
27974707-7	2017	Treatment with EW-7197, a novel inhibitor of TGF-beta signaling, diminished CUG2-mediated EMT and inhibition of Akt, ERK, JNK, and p38 MAPK, non-canonical TGF-beta signaling molecules, also decreased expression of Smad2/3, Snail and Twist, leading to inhibition of EMT.	vactosertib	15-22	AKT serine/threonine kinase 1	Homo sapiens	112-115
27974707-7	2017	Treatment with EW-7197, a novel inhibitor of TGF-beta signaling, diminished CUG2-mediated EMT and inhibition of Akt, ERK, JNK, and p38 MAPK, non-canonical TGF-beta signaling molecules, also decreased expression of Smad2/3, Snail and Twist, leading to inhibition of EMT.	vactosertib	15-22	mitogen-activated protein kinase 1	Homo sapiens	117-120
27974707-7	2017	Treatment with EW-7197, a novel inhibitor of TGF-beta signaling, diminished CUG2-mediated EMT and inhibition of Akt, ERK, JNK, and p38 MAPK, non-canonical TGF-beta signaling molecules, also decreased expression of Smad2/3, Snail and Twist, leading to inhibition of EMT.	vactosertib	15-22	mitogen-activated protein kinase 8	Homo sapiens	122-125
27974707-7	2017	Treatment with EW-7197, a novel inhibitor of TGF-beta signaling, diminished CUG2-mediated EMT and inhibition of Akt, ERK, JNK, and p38 MAPK, non-canonical TGF-beta signaling molecules, also decreased expression of Smad2/3, Snail and Twist, leading to inhibition of EMT.	vactosertib	15-22	transforming growth factor beta 1	Homo sapiens	155-163
27974707-7	2017	Treatment with EW-7197, a novel inhibitor of TGF-beta signaling, diminished CUG2-mediated EMT and inhibition of Akt, ERK, JNK, and p38 MAPK, non-canonical TGF-beta signaling molecules, also decreased expression of Smad2/3, Snail and Twist, leading to inhibition of EMT.	vactosertib	15-22	SMAD family member 2	Homo sapiens	214-221
27974707-7	2017	Treatment with EW-7197, a novel inhibitor of TGF-beta signaling, diminished CUG2-mediated EMT and inhibition of Akt, ERK, JNK, and p38 MAPK, non-canonical TGF-beta signaling molecules, also decreased expression of Smad2/3, Snail and Twist, leading to inhibition of EMT.	vactosertib	15-22	snail family transcriptional repressor 1	Homo sapiens	223-228
26845171-8	2016	In addition, EW-7197 inhibited HIF1alpha-derived HSC activation and expression of EMT markers in LX-2 cells in vitro.	vactosertib	13-20	hypoxia inducible factor 1 subunit alpha	Homo sapiens	31-40
26549110-2	2015	This study was undertaken to gain the proof of concept of a small-molecule inhibitor of TGF-beta type I receptor kinase, EW-7197 as a potent anti-cancer therapy for HCC.	vactosertib	121-128	transforming growth factor beta 1	Homo sapiens	88-96
26462028-4	2015	Blocking TGF-beta signaling with the TGF-beta type I receptor kinase (ALK5) inhibitor, EW-7197, suppresses paclitaxel-induced EMT and CSC properties such as mammosphere-forming efficiency (MSFE), aldehyde dehydrogenase (ALDH) activity, CD44+/CD24- ratio, and pluripotency regulators (Oct4, Nanog, Klf4, Myc, and Sox2).	vactosertib	87-94	transforming growth factor beta receptor 1	Homo sapiens	70-74
26462028-4	2015	Blocking TGF-beta signaling with the TGF-beta type I receptor kinase (ALK5) inhibitor, EW-7197, suppresses paclitaxel-induced EMT and CSC properties such as mammosphere-forming efficiency (MSFE), aldehyde dehydrogenase (ALDH) activity, CD44+/CD24- ratio, and pluripotency regulators (Oct4, Nanog, Klf4, Myc, and Sox2).	vactosertib	87-94	CD44 molecule (Indian blood group)	Homo sapiens	236-240
26462028-4	2015	Blocking TGF-beta signaling with the TGF-beta type I receptor kinase (ALK5) inhibitor, EW-7197, suppresses paclitaxel-induced EMT and CSC properties such as mammosphere-forming efficiency (MSFE), aldehyde dehydrogenase (ALDH) activity, CD44+/CD24- ratio, and pluripotency regulators (Oct4, Nanog, Klf4, Myc, and Sox2).	vactosertib	87-94	CD24 molecule	Homo sapiens	242-246
26462028-4	2015	Blocking TGF-beta signaling with the TGF-beta type I receptor kinase (ALK5) inhibitor, EW-7197, suppresses paclitaxel-induced EMT and CSC properties such as mammosphere-forming efficiency (MSFE), aldehyde dehydrogenase (ALDH) activity, CD44+/CD24- ratio, and pluripotency regulators (Oct4, Nanog, Klf4, Myc, and Sox2).	vactosertib	87-94	POU class 5 homeobox 1	Homo sapiens	284-288
26462028-4	2015	Blocking TGF-beta signaling with the TGF-beta type I receptor kinase (ALK5) inhibitor, EW-7197, suppresses paclitaxel-induced EMT and CSC properties such as mammosphere-forming efficiency (MSFE), aldehyde dehydrogenase (ALDH) activity, CD44+/CD24- ratio, and pluripotency regulators (Oct4, Nanog, Klf4, Myc, and Sox2).	vactosertib	87-94	Nanog homeobox	Homo sapiens	290-295
26462028-4	2015	Blocking TGF-beta signaling with the TGF-beta type I receptor kinase (ALK5) inhibitor, EW-7197, suppresses paclitaxel-induced EMT and CSC properties such as mammosphere-forming efficiency (MSFE), aldehyde dehydrogenase (ALDH) activity, CD44+/CD24- ratio, and pluripotency regulators (Oct4, Nanog, Klf4, Myc, and Sox2).	vactosertib	87-94	Kruppel like factor 4	Homo sapiens	297-301
26462028-4	2015	Blocking TGF-beta signaling with the TGF-beta type I receptor kinase (ALK5) inhibitor, EW-7197, suppresses paclitaxel-induced EMT and CSC properties such as mammosphere-forming efficiency (MSFE), aldehyde dehydrogenase (ALDH) activity, CD44+/CD24- ratio, and pluripotency regulators (Oct4, Nanog, Klf4, Myc, and Sox2).	vactosertib	87-94	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	303-306
26462028-4	2015	Blocking TGF-beta signaling with the TGF-beta type I receptor kinase (ALK5) inhibitor, EW-7197, suppresses paclitaxel-induced EMT and CSC properties such as mammosphere-forming efficiency (MSFE), aldehyde dehydrogenase (ALDH) activity, CD44+/CD24- ratio, and pluripotency regulators (Oct4, Nanog, Klf4, Myc, and Sox2).	vactosertib	87-94	SRY-box transcription factor 2	Homo sapiens	312-316
26549110-6	2015	In addition, EW-7197 inhibited TGF-beta-stimulated TIMP-1 secretion by HSCs as well as the TIMP-1-induced proliferation, motility, and survival of HCC cells.	vactosertib	13-20	TIMP metallopeptidase inhibitor 1	Homo sapiens	91-97
26549110-6	2015	In addition, EW-7197 inhibited TGF-beta-stimulated TIMP-1 secretion by HSCs as well as the TIMP-1-induced proliferation, motility, and survival of HCC cells.	vactosertib	13-20	transforming growth factor beta 1	Homo sapiens	31-39
26549110-6	2015	In addition, EW-7197 inhibited TGF-beta-stimulated TIMP-1 secretion by HSCs as well as the TIMP-1-induced proliferation, motility, and survival of HCC cells.	vactosertib	13-20	TIMP metallopeptidase inhibitor 1	Homo sapiens	51-57
34478262-3	2021	To surmount the pathological obstacle, we developed a size switchable nanosystem based on PEG-PLGA nanospheres encapsulated within liposomes for the combined delivery of vactosertib (VAC), a TGF-beta1 receptor kinase inhibitor, and the cytotoxic drug paclitaxel (TAX).	vactosertib	170-181	transforming growth factor beta 1	Homo sapiens	191-200
25487606-0	2015	EW-7197 inhibits hepatic, renal, and pulmonary fibrosis by blocking TGF-beta/Smad and ROS signaling.	vactosertib	0-7	transforming growth factor beta 1	Homo sapiens	68-76
25487606-4	2015	Western blot, immunofluorescence, siRNA, and ChIP analysis were carried out to characterize EW-7197 as a TGF-beta/Smad signaling inhibitor in LX-2, Hepa1c1c7, NRK52E, and MRC5 cells.	vactosertib	92-99	transforming growth factor beta 1	Homo sapiens	105-113
24127404-4	2013	Oral treatment with a novel ALK5 inhibitor, EW-7197 (2.5 mg/kg daily) or a representative ALK5 inhibitor, LY-2157299 (75 mg/kg bid) suppressed the progression of melanoma with enhanced cytotoxic T-lymphocyte (CTL) responses.	vactosertib	44-51	transforming growth factor, beta receptor I	Mus musculus	28-32
24786585-0	2014	Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-beta type I receptor kinase as cancer immunotherapeutic/antifibrotic agent.	vactosertib	123-130	transforming growth factor beta receptor 1	Homo sapiens	198-222
35390248-2	2022	Here we evaluated the anti-metastatic therapeutic potential of vactosertib, an orally bioavailable TGF-beta type I receptor (activin receptor-like kinase 5, ALK5) inhibitor, via suppression of radiation-induced EMT and CSC properties, oxidative stress generation, and breast to lung metastasis in a breast cancer mouse model and breast cancer cell lines.	vactosertib	63-74	transforming growth factor, beta receptor I	Mus musculus	157-161
34445093-10	2021	Pretreatment with EW-7197 prevented the effects of HMGB1.	vactosertib	18-25	high mobility group box 1	Homo sapiens	51-56
35390248-8	2022	CONCLUSIONS: These results indicate that inhibition of TGF-beta signaling with vactosertib in breast cancer patients undergoing radiotherapy would be an attractive strategy for the prevention of cancer metastasis and recurrence.	vactosertib	79-90	transforming growth factor alpha	Homo sapiens	55-63
35024955-8	2022	Knockdown of FOXO3 prevented the growth of cilia-like structures induced by EW-7197 or AG-1478 and induced cell migration under treatment with EW-7197.	vactosertib	76-83	forkhead box O3	Mus musculus	13-18
35024955-8	2022	Knockdown of FOXO3 prevented the growth of cilia-like structures induced by EW-7197 or AG-1478 and induced cell migration under treatment with EW-7197.	vactosertib	143-150	forkhead box O3	Mus musculus	13-18
33890869-8	2021	Treatment with follistatin, a potent inhibitor of activin, or vactosertib, which inhibits both TGFbetaR1 and the activin type I receptor ALK4, induced a profound inhibition of pSMAD in BrafV600E-PTCs.	vactosertib	62-73	activin A receptor, type 1B	Mus musculus	137-141
35255604-3	2022	We aimed to examine the effects of EW-7197, an inhibitor of TGF-beta type 1 receptor kinase (ALK5), in retarding the progression of DN, both in vivo, using a diabetic mouse model (db/db mice), and in vitro, in podocytes and mesangial cells.	vactosertib	35-42	transforming growth factor, beta receptor I	Mus musculus	93-97
35255604-11	2022	Treatment with EW-7197 significantly inhibited TGF-beta signaling, inflammation, apoptosis, reactive oxygen species, and endoplasmic reticulum stress in diabetic mice and renal cells.	vactosertib	15-22	transforming growth factor alpha	Mus musculus	47-55
35255604-13	2022	EW-7197 alleviates renal fibrosis and inflammation in diabetes by inhibiting downstream TGF-beta signaling, thereby retarding the progression of DN.	vactosertib	0-7	transforming growth factor alpha	Mus musculus	88-96
32076068-4	2020	Compared to nal-IRI/5-FU/LV treatment, combining nal-IRI/5-FU/LV with vactosertib, a TGF-beta signalling inhibitor, significantly improved long-term survival rates and effectively suppressed invasion to surrounding tissues.	vactosertib	70-81	transforming growth factor alpha	Mus musculus	85-93
32857676-5	2020	Pretreatment with EW-7197 prevented the changes of all tight junction molecules induced by HMGB1.	vactosertib	18-25	high mobility group box 1	Homo sapiens	91-96
32857676-6	2020	In 2.5D Matrigel culture, treatment with HMGB1 induced permeability of FITC-dextran (FD-4) into the lumen, whereas pretreatment with EW-7197 prevented the hyperpermeability of FD-4 into the lumen caused by HMGB1.	vactosertib	133-140	high mobility group box 1	Homo sapiens	206-211
32857676-8	2020	In the 2D culture of HLE cells with HMGB1, knockdown of p63 increased the level of angulin-1/LSR and CLDN-4, while pretreatment with EW-7197 enhanced the increase of CLDN-4 induced by knockdown of p63.	vactosertib	133-140	claudin 4	Homo sapiens	166-172
32857676-8	2020	In the 2D culture of HLE cells with HMGB1, knockdown of p63 increased the level of angulin-1/LSR and CLDN-4, while pretreatment with EW-7197 enhanced the increase of CLDN-4 induced by knockdown of p63.	vactosertib	133-140	tumor protein p63	Homo sapiens	197-200
32423802-8	2020	Treatment with EW-7197, a transforming growth factor-beta (TGF-beta) type I receptor kinase inhibitor, prevented all the effects of HMGB1 in Calu-3 cells.	vactosertib	15-22	tumor necrosis factor	Homo sapiens	26-57
32423802-8	2020	Treatment with EW-7197, a transforming growth factor-beta (TGF-beta) type I receptor kinase inhibitor, prevented all the effects of HMGB1 in Calu-3 cells.	vactosertib	15-22	high mobility group box 1	Homo sapiens	132-137
32423802-10	2020	The effects of HMGB1 contribute to TGF-beta signaling and EW-7197 shows potential for use in therapy for HMGB1-induced airway inflammation.	vactosertib	58-65	high mobility group box 1	Homo sapiens	105-110
31496148-1	2020	PURPOSE: To examine the therapeutic effect of Vactosertib, a small molecule inhibitor of transforming growth factor-beta (TGF-beta) type I receptor (activin receptor-like kinase-5, ALK5), in an experimental model of Peyronie"s disease (PD) and determining anti-fibrotic mechanisms of Vactosertib in primary fibroblasts derived from human PD plaques.	vactosertib	46-57	transforming growth factor beta receptor 1	Homo sapiens	181-185
31496148-7	2020	RESULTS: Vactosertib induced significant regression of fibrotic plaques in PD rats in vivo through reduced infiltration of inflammatory cells and reduced expression of phospho-Smad2, which recovered erectile function.	vactosertib	9-20	SMAD family member 2	Rattus norvegicus	176-181
31496148-8	2020	Vactosertib also abrogated TGF-beta1-induced enhancement of extracellular matrix protein production and hydroxyproline content in PD fibroblasts in vitro by hindering the TGF-beta1-induced Smad2/3 phosphorylation and nuclear translocation, and fibroblast-to-myofibroblast transdifferentiation.	vactosertib	0-11	transforming growth factor, beta 1	Rattus norvegicus	27-36
31496148-8	2020	Vactosertib also abrogated TGF-beta1-induced enhancement of extracellular matrix protein production and hydroxyproline content in PD fibroblasts in vitro by hindering the TGF-beta1-induced Smad2/3 phosphorylation and nuclear translocation, and fibroblast-to-myofibroblast transdifferentiation.	vactosertib	0-11	transforming growth factor, beta 1	Rattus norvegicus	171-180
31496148-8	2020	Vactosertib also abrogated TGF-beta1-induced enhancement of extracellular matrix protein production and hydroxyproline content in PD fibroblasts in vitro by hindering the TGF-beta1-induced Smad2/3 phosphorylation and nuclear translocation, and fibroblast-to-myofibroblast transdifferentiation.	vactosertib	0-11	SMAD family member 2	Rattus norvegicus	189-194
31300967-0	2020	Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study.	vactosertib	35-46	transforming growth factor beta receptor 1	Homo sapiens	54-84
31300967-1	2020	Purposes Vactosertib is a new investigational inhibitor of activin receptor-like kinase 5.	vactosertib	9-20	transforming growth factor beta receptor 1	Homo sapiens	59-89
32076068-6	2020	Particularly, the expression of tumour-suppressing gene Ccdc80 was induced by vactosertib and further induced by vactosertib in combination with nal-IRI/5-FU/LV.	vactosertib	78-89	coiled-coil domain containing 80	Mus musculus	56-62
32076068-6	2020	Particularly, the expression of tumour-suppressing gene Ccdc80 was induced by vactosertib and further induced by vactosertib in combination with nal-IRI/5-FU/LV.	vactosertib	113-124	coiled-coil domain containing 80	Mus musculus	56-62
32076068-8	2020	Collectively, these results indicate that combination treatment of vactosertib with nal-IRI/5-FU/LV improves overall survival rates in a mouse model of pancreatic cancer by suppressing invasion through CCDC80.	vactosertib	67-78	coiled-coil domain containing 80	Mus musculus	202-208
31138521-5	2019	Inhibiting TGFbeta signaling in NK cells using the TGFbeta receptor 1 (R1) inhibitor (EW-7197) significantly enhanced VAY736-induced NK cell-mediated ALL killing.	vactosertib	86-93	transforming growth factor beta 1	Homo sapiens	11-18
31138521-5	2019	Inhibiting TGFbeta signaling in NK cells using the TGFbeta receptor 1 (R1) inhibitor (EW-7197) significantly enhanced VAY736-induced NK cell-mediated ALL killing.	vactosertib	86-93	CD1b molecule	Homo sapiens	51-73
30135214-7	2018	Moreover, TEW7197, a specific TbetaR1 kinase inhibitor, reduces tumor formation in the NF2-model mouse (Postn-Cre;NF2f/f).	vactosertib	10-17	trace amine associated receptor 1	Homo sapiens	30-37
30135214-7	2018	Moreover, TEW7197, a specific TbetaR1 kinase inhibitor, reduces tumor formation in the NF2-model mouse (Postn-Cre;NF2f/f).	vactosertib	10-17	neurofibromin 2	Mus musculus	87-90
30135214-8	2018	Gene expression profiling reveals that TEW7197 treatment induces the expression of lipid metabolism-related gene set, such as NF2-restored cells in HEI-193 (NF2-deficient Schwannoma).	vactosertib	39-46	neurofibromin 2	Mus musculus	126-129
30135214-8	2018	Gene expression profiling reveals that TEW7197 treatment induces the expression of lipid metabolism-related gene set, such as NF2-restored cells in HEI-193 (NF2-deficient Schwannoma).	vactosertib	39-46	neurofibromin 2	Mus musculus	157-160